PEAK6 Investments L.P. acquired a new stake in Luminex Co. (NASDAQ:LMNX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,144 shares of the medical instruments supplier’s stock, valued at approximately $359,000.

Several other hedge funds and other institutional investors have also bought and sold shares of LMNX. BlackRock Inc. boosted its stake in shares of Luminex by 6.4% in the second quarter. BlackRock Inc. now owns 6,593,040 shares of the medical instruments supplier’s stock valued at $194,692,000 after purchasing an additional 395,549 shares during the period. Hancock Holding Co. purchased a new position in shares of Luminex in the first quarter valued at approximately $7,907,000. Acadian Asset Management LLC boosted its stake in shares of Luminex by 28.4% in the second quarter. Acadian Asset Management LLC now owns 1,576,596 shares of the medical instruments supplier’s stock valued at $46,552,000 after purchasing an additional 348,940 shares during the period. DAFNA Capital Management LLC boosted its stake in shares of Luminex by 810.0% in the first quarter. DAFNA Capital Management LLC now owns 227,500 shares of the medical instruments supplier’s stock valued at $4,793,000 after purchasing an additional 202,500 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Luminex by 5.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,951,636 shares of the medical instruments supplier’s stock valued at $41,121,000 after purchasing an additional 100,370 shares during the period. 82.23% of the stock is owned by institutional investors and hedge funds.

Shares of Luminex stock opened at $29.35 on Friday. Luminex Co. has a 52-week low of $18.62 and a 52-week high of $35.37. The company has a market capitalization of $1.31 billion, a P/E ratio of 32.25, a PEG ratio of 3.39 and a beta of 0.24.

Luminex (NASDAQ:LMNX) last released its quarterly earnings data on Monday, August 6th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.04). Luminex had a return on equity of 7.44% and a net margin of 10.57%. The company had revenue of $79.60 million for the quarter, compared to analyst estimates of $79.66 million. During the same period in the previous year, the business posted $0.26 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. equities research analysts forecast that Luminex Co. will post 0.58 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 12th. Shareholders of record on Friday, September 21st will be issued a dividend of $0.06 per share. The ex-dividend date is Thursday, September 20th. This represents a $0.24 dividend on an annualized basis and a yield of 0.82%. Luminex’s payout ratio is currently 26.37%.

In other Luminex news, Director G Walter Loewenbaum II sold 40,797 shares of the firm’s stock in a transaction that occurred on Friday, June 22nd. The shares were sold at an average price of $31.03, for a total transaction of $1,265,930.91. Following the sale, the director now owns 491,151 shares of the company’s stock, valued at $15,240,415.53. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is currently owned by company insiders.

Several research analysts have recently commented on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $27.00 price objective on shares of Luminex in a research note on Tuesday, August 7th. ValuEngine upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 19th. Zacks Investment Research downgraded shares of Luminex from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. BidaskClub upgraded shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 24th. Finally, Citigroup lifted their price target on shares of Luminex from $23.00 to $34.00 and gave the stock a “$33.58” rating in a research note on Monday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.60.

Luminex Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Recommended Story: Hedge Funds Explained

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.